ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Comfortably above the $2 NASDAQ delist line

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jan 18, 2024 1:02pm

135 Views

Post# 35833960

RE:RE:RE:Comfortably above the $2 NASDAQ delist line

Looks like we'll soon test "comfortable". The Boston group decided to do the dirty work just under $2 so presumably that's within shooting distance of whatever they need to keep it listed, and will do so. I had thought we were cruising in for a soft landing around $1.88 before the overshoot, but in the end it's all the same.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?